bevacizumab improves quality of life in patients with recurrent glioblastoma贝伐单抗改善复发胶质母细胞瘤患者的生活质量.pdfVIP

Hindawi Publishing Corporation Chemotherapy Research and Practice Volume 2011, Article ID 602812, 6 pages doi:10.1155/2011/602812 Clinical Study Bevacizumab Improves Quality of Life in Patients with Recurrent Glioblastoma Seema Nagpal,1, 2 Griffith Harsh,3 and Lawrence Recht1, 2 1 Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA 2 Advanced Medicine Center, 875 Blake Wilbur Drive, CC2221 Stanford, CA 94305, USA 3 Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA 94305, USA Correspondence should be addressed to Seema Nagpal, snagpal@ and Lawrence Recht, lrecht@ Received 18 April 2011; Revised 12 June 2011; Accepted 8 July 2011 Academic Editor: Evangelia D. Razis Copyright © 2011 Seema Nagpal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Objective. To quantify the benefits in survival and quality of life in patients receiving bevacizumab (BEV) for recurrent glioblastoma (GBM). Methods. This is a retrospective study of 40 adult patients with recurrent GBM treated between 2005 and 2009 at a single institution. All patients had initial treatment with surgery, radiation, and concurrent temozolomide, then monthly temozolomide. Over 250 charts were screened. Sufficient data was available for 20 patients treated with BEV and 20 patients who did not receive BEV at the time of recurrence. The independent living score (ILS), designed to reward long-term independent survival, was calculated for each patient. Results. The mean ILS was nearly double in the BEV group compared to the No-BEV group (15.0 versus 8.2, P = 0.